LIPELLA PHARMACEUTICALS INC (LIPO)
US53630L1008 - Common Stock
Overall LIPO gets a fundamental rating of 2 out of 10. We evaluated LIPO against 573 industry peers in the Biotechnology industry. While LIPO seems to be doing ok healthwise, there are quite some concerns on its profitability. LIPO does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
LIPO had negative earnings in the past year.
In the past year LIPO has reported a negative cash flow from operations.
In the past 5 years LIPO always reported negative net income.
In the past 5 years LIPO always reported negative operating cash flow.
1.2 Ratios
LIPO has a Return On Assets of -189.66%. This is amonst the worse of the industry: LIPO underperforms 90.14% of its industry peers.
LIPO has a Return On Equity of -243.13%. This is in the lower half of the industry: LIPO underperforms 72.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -189.66% | ||
| ROE | -243.13% | ||
| ROIC | N/A |
ROA(3y)-88.49%
ROA(5y)-64.78%
ROE(3y)-111.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LIPO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
LIPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LIPO has been increased compared to 1 year ago.
LIPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
Based on the Altman-Z score of -9.25, we must say that LIPO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.25, LIPO is not doing good in the industry: 74.30% of the companies in the same industry are doing better.
LIPO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.25 |
ROIC/WACCN/A
WACC10.27%
2.3 Liquidity
LIPO has a Current Ratio of 4.33. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 4.33, LIPO perfoms like the industry average, outperforming 48.42% of the companies in the same industry.
LIPO has a Quick Ratio of 4.33. This indicates that LIPO is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 4.33, LIPO perfoms like the industry average, outperforming 49.82% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.33 | ||
| Quick Ratio | 4.33 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.62% over the past year.
The Revenue has grown by 24.04% in the past year. This is a very strong growth!
Measured over the past years, LIPO shows a very negative growth in Revenue. The Revenue has been decreasing by -22.39% on average per year.
EPS 1Y (TTM)33.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%53.95%
Revenue 1Y (TTM)24.04%
Revenue growth 3Y-22.39%
Revenue growth 5YN/A
Sales Q2Q%27.89%
3.2 Future
The Earnings Per Share is expected to grow by 13.01% on average over the next years. This is quite good.
Based on estimates for the next years, LIPO will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y27.09%
EPS Next 2Y21.23%
EPS Next 3Y13.01%
EPS Next 5YN/A
Revenue Next Year-36.03%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for LIPO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LIPO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LIPO's earnings are expected to grow with 13.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.23%
EPS Next 3Y13.01%
5. Dividend
5.1 Amount
No dividends for LIPO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIPELLA PHARMACEUTICALS INC
NASDAQ:LIPO (9/18/2024, 8:13:10 PM)
After market: 0.4006 +0.01 (+2.67%)0.3902
-0.02 (-3.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap3.12M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -189.66% | ||
| ROE | -243.13% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 4.33 | ||
| Quick Ratio | 4.33 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)33.62%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y27.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)24.04%
Revenue growth 3Y-22.39%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y